Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Irinotecan HCl trihydrate (formerly CPT-11; CPT 11; Irinophore C; Irinotecan lactone; Irinotecanum ), the hydrochloride salt and trihydrated form of irinotecan which is an antitumor drug and a soluble prodrug of SN-38, is a semisynthetic derivative of camptothecin approved for cancer treatment. It suppresses P388 leukemia's ability to proliferate with an IC50 value of 3.4μM. Irinotecan was created to prevent toxicity and boost camptothecin's therapeutic effectiveness.
Targets |
Topoisomerase I
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
In 20 cm2 dishes, exponentially growing cells are seeded with the ideal number of cells for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They receive treatment with irinotecan or SN-38 at increasing concentrations for a single cell doubling period (24 hours for LoVo cells and 40 hours for HT-29 cells) after two days. Following a 0.15 M NaCl wash, the cells are cultured in normal medium for two more doubling times before being separated from the support using trypsin-EDTA and counted using a hemocytometer. Subsequently, the drug concentrations that cause a 50% inhibition of growth in cells treated with the drug are estimated as the IC50 values[2].
|
|
Animal Protocol |
|
|
References |
|
Molecular Formula |
C33H45CLN4O9
|
|
---|---|---|
Molecular Weight |
677.18
|
|
Exact Mass |
676.29
|
|
Elemental Analysis |
C, 58.53; H, 6.70; Cl, 5.23; N, 8.27; O, 21.26
|
|
CAS # |
136572-09-3
|
|
Appearance |
Yellow solid powder
|
|
SMILES |
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.O.O.O.Cl
|
|
InChi Key |
KLEAIHJJLUAXIQ-JDRGBKBRSA-N
|
|
InChi Code |
InChI=1S/C33H38N4O6.ClH.3H2O/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;;;;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H;3*1H2/t33-;;;;/m0..../s1
|
|
Chemical Name |
[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;trihydrate;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.4767 mL | 7.3836 mL | 14.7671 mL | |
5 mM | 0.2953 mL | 1.4767 mL | 2.9534 mL | |
10 mM | 0.1477 mL | 0.7384 mL | 1.4767 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02192359 | Active Recruiting |
Drug: Irinotecan Hydrochloride Drug: Irinotecan |
Recurrent Glioblastoma Recurrent Gliosarcoma |
City of Hope Medical Center | March 7, 2016 | Phase 1 |
NCT00045201 | Active Recruiting |
Drug: Erlotinib Hydrochloride Drug: Irinotecan Hydrochloride |
Adult Solid Neoplasm | National Cancer Institute (NCI) |
June 13, 2002 | Phase 1 |
NCT03290937 | Active Recruiting |
Drug: Irinotecan Hydrochloride Biological: Cetuximab |
Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 |
M.D. Anderson Cancer Center | December 27, 2017 | Phase 1 |
NCT03794349 | Recruiting | Drug: Irinotecan Hydrochloride Biological: Dinutuximab |
High Risk Neuroblastoma Recurrent Neuroblastoma |
Children's Oncology Group | July 8, 2019 | Phase 2 |
NCT00576654 | Active Recruiting |
Drug: Irinotecan Hydrochloride Drug: Veliparib |
Hodgkin Lymphoma Non-Hodgkin Lymphoma |
National Cancer Institute (NCI) |
December 5, 2007 | Phase 1 |